Cancer Therapy
Gefitinib used to treat non-small cell lung cancer
Published in Vaccine Weekly, March 1st, 2006
"The ZD1839 (Iressa, gefitinib) treatment in phase I trials for patients with advanced NSCLC was associated with disease stabilization and tumor regression. The aim of this study was to analyze the efficacy of gefitinib monotherapy as a second- or third-line treatment for locally-advanced and advanced NSCLC," investigators in Hungary reported.
"Data for 50 patients were analyzed. Patients were treated at 5 centers in Hungary as part of the gefitinib Expanded Access Program (EAP). The response rate was 10% (all partial responses), with disease stabilization in 46% of patients....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-03-01)
More Articles from Vaccine Weekly
- Epidemiology
Influenza immunization in children reduces influenza illnesses of unvaccinated elderly - Influenza Vaccines
Modified surfactant stimulates IgA in response to influenza antigen - Measles Vaccines
More sclerosing panencephalitis is prevented by measles vaccine than recognized - Vaccine Delivery
Dendritic cells were targeted using pH-responsive microparticle vaccine carriers - Vaccine Development
Hookworms impair immune response to exogenous antigen during infection - Adenovirus Vector
Rabbit VH domain antibody polyspecific to c-Met and adenoviral knob protein is generated - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
